Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Boerne, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Boerne, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Dallas, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
El Paso, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Live Oak, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Live Oak, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
New Braunfels, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Plano, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
San Antonio, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
San Antonio, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
San Antonio, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Waco, TX
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Waco, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Burlington, VT
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Henrico, VA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Henrico, VA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Richmond, VA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Bellingham, WA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Bellingham, WA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Seattle, WA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Seattle, WA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Spokane, WA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Vancouver, WA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Greenfield, WI
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Greenfield, WI
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
La Crosse, WI
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
La Crosse, WI
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Madison, WI
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
West Allis, WI
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
West Allis, WI
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Raj K. Maturi, MD
mi
from
Indianapolis, IN
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Raj K. Maturi, MD
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Beetham Eye Institute
mi
from
Boston, MA
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Beetham Eye Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Palmetto Retina Center
mi
from
West Columbia, SC
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Palmetto Retina Center
mi
from
West Columbia, SC
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Valley Retina Institute, P.A.
mi
from
McAllen, TX
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
A Phase II, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of XG-104 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAESM ) Model for the Treatment of Dry Eye
Status: Enrolling
Updated:  9/9/2014
Andover Eye Associates
mi
from
Andover, MA
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
A Phase II, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of XG-104 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAESM ) Model for the Treatment of Dry Eye
Status: Enrolling
Updated: 9/9/2014
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  9/15/2014
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 9/15/2014
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (ROTATE Trial)
Status: Enrolling
Updated:  9/16/2014
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (ROTATE Trial)
Status: Enrolling
Updated: 9/16/2014
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Click here to add this to my saved trials
Investigating Optical and Neural Causes of Vision Loss
Investigating Optical and Neural Causes of Vision Loss
Status: Enrolling
Updated:  9/18/2014
Jesse Brown VAMC (WestSide Division)
mi
from
Chicago, IL
Investigating Optical and Neural Causes of Vision Loss
Investigating Optical and Neural Causes of Vision Loss
Status: Enrolling
Updated: 9/18/2014
Jesse Brown VAMC (WestSide Division)
mi
from
Chicago, IL
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Jones Eye Institute - UAMS
mi
from
Little Rock, AR
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Jones Eye Institute - UAMS
mi
from
Little Rock, AR
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Shiley Eye Center - UCSD
mi
from
La Jolla, CA
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Shiley Eye Center - UCSD
mi
from
La Jolla, CA
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Loma Linda University
mi
from
Loma Linda, CA
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Loma Linda University
mi
from
Loma Linda, CA
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Colorado Retina Assoc.
mi
from
Denver, CO
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Colorado Retina Assoc.
mi
from
Denver, CO
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Eldorado Retina Associates
mi
from
Louisville, CO
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Eldorado Retina Associates
mi
from
Louisville, CO
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Yale Univ. Eye Center
mi
from
New Haven, CT
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Yale Univ. Eye Center
mi
from
New Haven, CT
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
University of Florida Health Science Center
mi
from
Jacksonville, FL
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
University of Florida Health Science Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Bascom Palmer Eye Institute
mi
from
Miami, FL
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Bascom Palmer Eye Institute
mi
from
Miami, FL
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Sarasota Retina Institute
mi
from
Sarasota, FL
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Sarasota Retina Institute
mi
from
Sarasota, FL
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Emory University Eye Center
mi
from
Atlanta, GA
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Emory University Eye Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Georgia Retina, P.C.
mi
from
Decatur, GA
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Georgia Retina, P.C.
mi
from
Decatur, GA
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Retina Associates of Kentucky
mi
from
Lexington, KY
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Retina Associates of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Wilmer Eye Institute
mi
from
Baltimore, MD
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Wilmer Eye Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Elman Retina Group, PA
mi
from
Baltimore, MD
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Elman Retina Group, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Retina Group of Washington
mi
from
Chevy Chase, MD
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Retina Group of Washington
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Ophthalmic Cons. of Boston
mi
from
Boston, MA
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Ophthalmic Cons. of Boston
mi
from
Boston, MA
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Kresge Eye Institute
mi
from
Detroit, MI
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Kresge Eye Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated:  10/2/2014
Vision Research Foundation
mi
from
Grand Rapids, MI
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)
Status: Enrolling
Updated: 10/2/2014
Vision Research Foundation
mi
from
Grand Rapids, MI
Click here to add this to my saved trials